Regeneron (REGN) shares rallied 3% in the last trading session to close at $905. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.7% gain over the past four weeks.The going has been good for Regeneron post the FDA approval of higher dose of its lead opthalmology drug Eylea. Regeneron recently won a lawsuit against Viatris for a proposed biosimilar of Eylea, which in turn wards off any biosimilar competition ...